StockpollyBeta
Get App
Popularity #4,294
ACTU · NASDAQ · Biotechnology

Actuate Therapeutics (ACTU)

Develops elraglusib, a GSK-3β inhibitor, for metastatic pancreatic cancer.

$0.7415
vs last close−0.07 (−8.16%)

  1. Actuate Announces Promising Preclinical Data Showing Synergistic Activity of Elraglusib in Combination with RAS Inhibitors Zoldonrasib and Daraxonrasib

    GlobeNewsWireClinical

  2. All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

    Zacks Investment ResearchPrice target

  3. Actuate Therapeutics' Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma

    GlobeNewsWire

  4. Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer

    GlobeNewsWire

  5. Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program

    GlobeNewsWire

  6. Analysts see 200%+ upside in these 3 high-risk stocks: here's why?

    Invezz

  7. Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors

    GlobeNewsWire

  8. Actuate Therapeutics drug improves survival odds in pancreatic cancer trial

    Reuters

  9. Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

    GlobeNewsWire

  10. Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers

    Accesswire

  11. Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors

    GlobeNewsWire

  12. Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers

    Globe News Wire

  13. Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026

    GlobeNewsWire

  14. Todd Thomson Sells 280,000 Shares of Actuate Therapeutics (NASDAQ:ACTU) Stock

    Defense World

  15. Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers

    GlobeNewsWire

  16. Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

    Zacks Investment Research

  17. Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026

    GlobeNewsWire

  18. How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

    Zacks Investment Research

  19. Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months

    GlobeNewsWire

  20. Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock

    GlobeNewsWire

  21. Actuate Therapeutics Announces Proposed Public Offering of Common Stock

    GlobeNewsWire

  22. Actuate Therapeutics Advances Clinical Program in Ewing Sarcoma After Positive Phase 1 Trial Demonstrates Complete and Partial Responses in Difficult-to-Treat Pediatric Sarcomas

    GlobeNewsWire

  23. Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial

    GlobeNewsWire

  24. Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO

    GlobeNewsWire